HCM
ARRY

Highbridge Capital Management’s Array Biopharma Inc ARRY Stock Holding History

Highbridge Capital Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-48,242
Closed -$404K – 1910
2017
Q2 		$404K Buy
+48,242
New +$395K 0.01% 831
2016
Q4 		– Sell
-144,790
Closed -$977K – 1751
2016
Q3 		$977K Buy
144,790
+109,852
+314% +$425K 0.02% 576
2016
Q2 		$125K Buy
34,938
+15,257
+78% +$49.7K ﹤0.01% 1294
2016
Q1 		$58K Sell
19,681
-362,637
-95% -$1.09M ﹤0.01% 1424
2015
Q4 		$1.61M Buy
+382,318
New +$1.74M 0.02% 588
2015
Q3 		– Sell
-18,474
Closed -$133K – 1946
2015
Q2 		$133K Buy
+18,474
New +$136K ﹤0.01% 1325
2015
Q1 		– Sell
-195,712
Closed -$925K – 1694
2014
Q4 		$925K Buy
+195,712
New +$774K 0.01% 669
2013
Q3 		– Sell
-77,864
Closed -$354K – 1611
2013
Q2 		$354K Buy
+77,864
New +$419K ﹤0.01% 988

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Highbridge Capital Management's ARRY Position: Q3 2017 in Review

Highbridge Capital Management sold out of Array Biopharma Inc (ARRY) in Q3 2017, closing a stake of 48,242 shares — an estimated $404K sold.

Highbridge Capital Management first reported a position in ARRY in Q2 2013 and held it in 8 quarters. The position peaked at $1.61M in Q4 2015. 184 funds tracked by Wall St. Rank hold ARRY as of Q3 2017.

  • Highbridge Capital Management reported no remaining Array Biopharma Inc position as of Q3 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 48,242 Array Biopharma Inc shares in Q3 2017, an estimated $404K.
  • Highbridge Capital Management first reported a position in Array Biopharma Inc in Q2 2013 and held it in 8 quarters.
  • Highbridge Capital Management's Array Biopharma Inc position peaked at $1.61M in Q4 2015.
  • 184 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2017.

Based on Highbridge Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.